mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2008-509mrj-194Research ArticleСтатьиArticlesПерспективы применения современного противовоспалительного препарата мелоксикам (Амелотекс) в клинической практикеPBOSPECTS FOR CLINICAL APPLICATION OF THE CURRENT ANTI-INFLAMMATORY DRUG MELOXICAM (AMELOTEX)EliseevM SEliseevM S-EliseyevM SEliseyevM S-20080912200824№4 (2008)5456Copyright © Eliseev M.S., Eliseyev M.S., 20082008Eliseev M.S., Eliseyev M.S.Eliseev M.S., Eliseyev M.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/194

Представлены данные об эффективности, безопасности, переносимости, основных механизмах действия, перспективах применения в клинической практике мелоксикама - современного селективного в отношении циклооксигеназы 2 нестероидного противовоспалительного препарата. Показаны преимущества инъекционной формы мелоксикама, характеризующейся быстрым и продолжительным анальгетическим действием.

The paper presents data on the effectiveness, safety, tolerance, major mechanisms of action, and prospects for clinically using meloxicam, a current selective nonsteroidal anti-inflammatory drug, against cyclooxygenase-2. It describes the advantages of meloxicam for injections, which begins acting promptly and shows an adequate long analgesic effect.

References<div><p>Griffin M.R. Epidemiology of nonsteroidal anti-inflammator drug-associated gastrointestinal injury. Am J Med 1998; 104: 23-9.</p><p>Prescription Pricing Authority. Analgesics and NSAIDs prescribing. PACT centre pages. URL: &lt;http://www.ppa.org.uk/news/pact-042002.htm&gt;. Accessed 31 January 2004.</p><p>Masferrer J.L., Seibert K., Zweifel B.S. et al. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci USA 1992; 89: 3917-21.</p><p>Насонов Е.Л. Противовоспалительная терапия ревматических болезней. М.: М-Сити, 1996; 60-72.</p><p>Flower R. The roles of COX-1 and COX-2: implications for NSAID development. Curr Opin Rheum 1996; 9(suppl. 1): 9-13.</p><p>Needleman P., Isakson P.C. The disciovery and function of COX-2. J Rheum 1997; 24(suppl. 49): 6-8.</p><p>Vane G.R., Bakchle Y.S. Bolting R.M. Cyclooxygenase 1 and 2. Ann Rev Pharmacol Toxicol 1998; 38: 97-120.</p><p>Насонов Е.Л. Нестероидные противовоспалительные препараты (перспективы применения в медицине). М., 2000; 143.</p><p>Chen Y.-F., Jobanputra P., Barton P. et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technology Assessment 2008; 12(11).</p><p>Trck D., Busch U., Heinzel G. et al. Effect of food on the pharmacokinetics of meloxicam after oral administration. Clin Drug Invest 1995; 9: 270-6.</p><p>Trck D., Busch U., Heinzel G. Clinical pharmacokinetics of meloxicam. Eur J Rheumatol Inflamm 1995; 15: 22-34.</p><p>Lapicque F., Vergne P., Jouzeau J.-I. et al. Articular diffusion of meloxicam after a single oral dose: relationship to cyclo-oxygenase inhibition in synovial cells. Clin Pharmacokinet 2000; 39: 369-82.</p><p>Schmid J., Busch U., Heinzel G. et al. Local tissue tolerability of meloxicam, a new NSAID: indication for parenteral, dermal and mucosal administration. Br J Rheumatol 1996; 35(suppl. 1): 44-50.</p><p>Meineke I., Tь rck D. Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients. Br J Clin Pharmacol 2003; 55: 32-8.</p><p>Busch U., Heinzel G., Naarjes H. et al. Pharmacokinetics of meloxicam in patients with liver insufficiency associated with liver cirrhosis. Rheum in Europe 1995; 24(suppl. 3): 177(C123).</p><p>Hawkey C., Kahan A., Steinbruck K. et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol 1998; 1998; 37: 937-45.</p><p>Dequeker J., Hawkey C., Kahan A. et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998; 37: 946-51.</p><p>Chen Y-F, Jobanputra P., Barton P. et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technology Assessment 2008; 12(11).</p><p>Valat J.P., Accardo S., Reginster J.Y. et al. A comparison of the efficacy and tolerability of meloxicam and diclofenac in the treatment of patients with osteoarthritis of the lumbar spine. Inflamm Res 2001; 50(1): 30-4.</p><p>Thompson J.P., Sharpe P., Kiani S. et al. Effect of meloxicam on postoperative pain after abdominal hysterectomy. Br J Anaesth 2000; 84: 151-4.</p><p>Ruperto N., Nikishina I., Pachanov E. et al. A Randomized, Double-Blind Clinical Trial of Two Doses of Meloxicam Compared With Naproxen in Children With Juvenile Idiopathic Arthritis. Arthr Rheum 2005; 52(2): 563-72.</p><p>Degner F., Lanes S., van Ryn J. et al. Pharmacological and clinical profill of meloxicam. In: Therapeutic robes of Selective COX2 inhibitors Ed. Vane J.R. and Batting R.M. 2001; 23: 498-523.</p><p>Del Tacca M., Colucci R., Fornai M. et al. Efficacy and Tolerability of Meloxicam, a COX-2 Preferential Nonsteroidal Anti-Inflammatory Drug Clin Drug Invest 2002; 22(12): 799-818.</p><p>Prieto A., De Barrio M., Martin E. Nabumetone and Meloxicam Well Tolerated in NSAID-Intolerant Subjects. J Allergy Clin Immunol 2007; 119(4): 960-64.</p><p>Naruse T., Nishida Y., Hosono K. et al. Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis 2006; 27(3): 584-92.</p><p>Combe B., Velicitat P, Garzon N. et al. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients. Inflamm Res 2001; 50(suppl. 1): 10-6.</p><p>Euller-Ziegler L., Velicitat P., Bluhmki E. et al. B.Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration. Inflamm Res 2001; 50(suppl. 1): 5-9.</p><p>Цветкова Е.С. Эффективность и переносимость ступенчатой терапии мовалисом (мелоксикамом) при ревматических заболеваниях. Тер арх 2004; 76(12): 78-80.</p></div><br /><div><p>Griffin M.R. Epidemiology of nonsteroidal anti-inflammator drug-associated gastrointestinal injury. Am J Med 1998; 104: 23-9.</p><p>Prescription Pricing Authority. Analgesics and NSAIDs prescribing. PACT centre pages. URL: &lt;http://www.ppa.org.uk/news/pact-042002.htm&gt;. Accessed 31 January 2004.</p><p>Masferrer J.L., Seibert K., Zweifel B.S. et al. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci USA 1992; 89: 3917-21.</p><p>Насонов Е.Л. Противовоспалительная терапия ревматических болезней. М.: М-Сити, 1996; 60-72.</p><p>Flower R. The roles of COX-1 and COX-2: implications for NSAID development. Curr Opin Rheum 1996; 9(suppl. 1): 9-13.</p><p>Needleman P., Isakson P.C. The disciovery and function of COX-2. J Rheum 1997; 24(suppl. 49): 6-8.</p><p>Vane G.R., Bakchle Y.S. Bolting R.M. Cyclooxygenase 1 and 2. Ann Rev Pharmacol Toxicol 1998; 38: 97-120.</p><p>Насонов Е.Л. Нестероидные противовоспалительные препараты (перспективы применения в медицине). М., 2000; 143.</p><p>Chen Y.-F., Jobanputra P., Barton P. et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technology Assessment 2008; 12(11).</p><p>Trck D., Busch U., Heinzel G. et al. Effect of food on the pharmacokinetics of meloxicam after oral administration. Clin Drug Invest 1995; 9: 270-6.</p><p>Trck D., Busch U., Heinzel G. Clinical pharmacokinetics of meloxicam. Eur J Rheumatol Inflamm 1995; 15: 22-34.</p><p>Lapicque F., Vergne P., Jouzeau J.-I. et al. Articular diffusion of meloxicam after a single oral dose: relationship to cyclo-oxygenase inhibition in synovial cells. Clin Pharmacokinet 2000; 39: 369-82.</p><p>Schmid J., Busch U., Heinzel G. et al. Local tissue tolerability of meloxicam, a new NSAID: indication for parenteral, dermal and mucosal administration. Br J Rheumatol 1996; 35(suppl. 1): 44-50.</p><p>Meineke I., Tь rck D. Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients. Br J Clin Pharmacol 2003; 55: 32-8.</p><p>Busch U., Heinzel G., Naarjes H. et al. Pharmacokinetics of meloxicam in patients with liver insufficiency associated with liver cirrhosis. Rheum in Europe 1995; 24(suppl. 3): 177(C123).</p><p>Hawkey C., Kahan A., Steinbruck K. et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol 1998; 1998; 37: 937-45.</p><p>Dequeker J., Hawkey C., Kahan A. et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998; 37: 946-51.</p><p>Chen Y-F, Jobanputra P., Barton P. et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technology Assessment 2008; 12(11).</p><p>Valat J.P., Accardo S., Reginster J.Y. et al. A comparison of the efficacy and tolerability of meloxicam and diclofenac in the treatment of patients with osteoarthritis of the lumbar spine. Inflamm Res 2001; 50(1): 30-4.</p><p>Thompson J.P., Sharpe P., Kiani S. et al. Effect of meloxicam on postoperative pain after abdominal hysterectomy. Br J Anaesth 2000; 84: 151-4.</p><p>Ruperto N., Nikishina I., Pachanov E. et al. A Randomized, Double-Blind Clinical Trial of Two Doses of Meloxicam Compared With Naproxen in Children With Juvenile Idiopathic Arthritis. Arthr Rheum 2005; 52(2): 563-72.</p><p>Degner F., Lanes S., van Ryn J. et al. Pharmacological and clinical profill of meloxicam. In: Therapeutic robes of Selective COX2 inhibitors Ed. Vane J.R. and Batting R.M. 2001; 23: 498-523.</p><p>Del Tacca M., Colucci R., Fornai M. et al. Efficacy and Tolerability of Meloxicam, a COX-2 Preferential Nonsteroidal Anti-Inflammatory Drug Clin Drug Invest 2002; 22(12): 799-818.</p><p>Prieto A., De Barrio M., Martin E. Nabumetone and Meloxicam Well Tolerated in NSAID-Intolerant Subjects. J Allergy Clin Immunol 2007; 119(4): 960-64.</p><p>Naruse T., Nishida Y., Hosono K. et al. Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis 2006; 27(3): 584-92.</p><p>Combe B., Velicitat P, Garzon N. et al. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients. Inflamm Res 2001; 50(suppl. 1): 10-6.</p><p>Euller-Ziegler L., Velicitat P., Bluhmki E. et al. B.Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration. Inflamm Res 2001; 50(suppl. 1): 5-9.</p><p>Цветкова Е.С. Эффективность и переносимость ступенчатой терапии мовалисом (мелоксикамом) при ревматических заболеваниях. Тер арх 2004; 76(12): 78-80.</p></div><br />

The authors declare that there are no conflicts of interest present.